Divamics is making waves in drug discovery for metabolic diseases by leveraging AI and molecular dynamics for groundbreaking therapeutic advancements.

Divamics showcased its leading autoimmune program DVI-001 and introduced the new metabolic program DVI-004 at JPM Week 2026, emphasizing AI's role in biotech.

SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- Divamics (DIVAMICS), an AI-driven biotechnology company specializing in high-precision molecular discovery, highlighted the significant advancement of its internal pipeline during the Biotech Showcase™ at JPM Week 2026. The company provided...